Synergy Pharmaceuticals Inc. (NASDAQ:SGYP): John Paulson’s Paulson & Co filed an amended 13D.
You can check out Paulson & Co’s latest holdings and filings here.
Please follow Paulson & Co (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Paulson & Co or update its stock holdings.
Follow John Paulson's Paulson & Co
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Paulson Co. Inc | 4,400,000 | 0 | 4,400,000 | 0 | 4,400,000 | 1.78% |
Follow John Paulson's Paulson & Co
Page 1 of 5 – SEC Filing
(Amendment No. 2)*
Follow Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Follow Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Page 2 of 5 – SEC Filing
1. | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
Paulson & Co. Inc. | |
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) [ ] | |
(b) [x] | |
3. | SEC USE ONLY |
4. | CITIZENSHIP OR PLACE OF ORGANIZATION |
State of Delaware | |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: | |
5. | SOLE VOTING POWER |
4,400,000 (See Note 1 to Item 4 below) | |
6. | SHARED VOTING POWER |
0 | |
7. | SOLE DISPOSITIVE POWER |
4,400,000 (See Note 1 to Item 4 below) | |
8. | SHARED DISPOSITIVE POWER |
0 | |
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
4,400,000 (See Note 1 to Item 4 below) | |
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
1.78% | |
12. | TYPE OF REPORTING PERSON |
IA |
Follow Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Follow Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Page 3 of 5 – SEC Filing
Item 1(a). | Name of Issuer: |
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
Item 2(a). | Name of Persons Filing: |
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
Item 2(c). | Citizenship: |
Item 2(d). | Title of Class of Securities: |
Item 2(e). | CUSIP Number: |
Item 3. | If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
(a) | [ ] | Broker or dealer registered under Section 15 of the Exchange Act. | |
(b) | [ ] | Bank as defined in Section 3(a)(6) of the Exchange Act. | |
(c) | [ ] | Insurance company defined in Section 3(a)(19) of the Exchange Act. | |
(d) | [ ] | Investment company registered under Section 8 of the Investment Company Act. | |
(e) | [X] | Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). | |
(f) | [ ] | Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). | |
(g) | [ ] | Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). | |
(h) | [ ] | Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. | |
(i) | [ ] | Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; | |
(j) | [ ] | Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J). | |
(k) | [ ] | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ |
Follow Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Follow Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Page 4 of 5 – SEC Filing
(a) | Amount beneficially owned: 4,400,000 (see Note 1) |
(b) | Percent of Class: 1.78% |
(c) | Number of shares as to which such person has: |
(i) | Sole power to vote or to direct the vote: 4,400,000 (See Note 1) |
(iii) | Sole power to dispose or to direct the disposition of: 4,400,000 (See Note 1) |
Item 5. | Ownership of Five Percent or Less of a Class. |
Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. |
Item 8. | Identification and Classification of Members of the Group. |
Item 9. | Notice of Dissolution of Group. |
Item 10. | Certification. |
Follow Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Follow Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)
Page 5 of 5 – SEC Filing
Stuart L. Merzer,
General Counsel & Chief Compliance Officer